The science of nations: European multinationals and American biotechnology
International Journal of Biotechnology · 1999
DOI: 10.1504/ijbt.1999.004480 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biotechnology, 1999. Verfasst von Margaret Sharp. Die Arbeit wurde bisher 12-mal zitiert (Crossref).
Abstract (Originalsprache)
This paper examines how Europe's large chemical/pharmaceutical multinationals have developed their interests and capabilities in biotechnology and in particular the degree to which, in the process, they have become increasingly linked into the US science base. It looks at both direct linkages via subsidiary laboratories located on US soil and at indirect linkages via the small, dedicated biotechnology companies. It concludes that, although the picture is mixed, many of these major European firms are now deeply embedded by these two routes into the American science base. However, far from this being "exploitation", the US in most respects is the gainer, for these linkages are creating high value added jobs for Americans on American soil. For Europe, the key issue is how far these firms are internally transferring the technology back to home-based laboratories. Unless this is happening, Europe risks the cumulative loss of leading edge capabilities.
Zitieren
APA
Sharp, M. (1999). The science of nations: European multinationals and American biotechnology. International Journal of Biotechnology. https://doi.org/10.1504/ijbt.1999.004480
Vancouver
Sharp M. The science of nations: European multinationals and American biotechnology. International Journal of Biotechnology. 1999. doi:10.1504/ijbt.1999.004480
BibTeX
@article{Sharp1999,
author = {Sharp, Margaret},
title = {The science of nations: European multinationals and American biotechnology},
journal = {International Journal of Biotechnology},
year = {1999},
doi = {10.1504/ijbt.1999.004480}
}
EUVIMED